DAVID ALLEN: Open Payments
NPI 1952371163 · HOLTON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$641 in 40 payments from 16 companies in 2025. Trend: 2023 $412 · 2024 $759 · 2025 $641
Food & beverage: $641
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59 |
| Novartis Pharmaceuticals Corporation | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| Ascensia Diabetes Care Us Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Novo Nordisk Inc | 2 | $29 |
| Amgen Inc. | 2 | $29 |
| Verona Pharma, Inc. | 2 | $27 |
Products named: VRAYLAR, CAPLYTA, XIFAXAN, UBRELVY, LEQVIO, AIRSUPRA, EOHILIA, Wegovy.
Industry payments across KS — which companies pay providers there.
